Results 61 to 70 of about 15,597 (227)

The Psychedelic Influence on Philosophy [PDF]

, 2016
A mildly chronological overview of the philosophers who may have been inspired by the use of psychoactive chemicals, inc. Plato, de Quincey, Davy, Schopenhauer, Nietzsche, James, Bergson, Benjamin, Jünger, Paz, Marcuse, Sartre, Foucault; and a mention of
Sjöstedt-H., Peter
core  

The effect of particular active substances of hallucinogenic mushrooms [PDF]

, 2014
This mini review presents the influence of psilocybin, psilocin, ibotenic acid and muscimol on the nervous system. Also the effects of the above mentioned substances on emotion and mental health of people are discussed.Grzyby halucynogenne są spożywane ...
Wieczorek, Marek
core   +2 more sources

Unlocking ‘stuckness’ and catalysing change: A qualitative study of clinician and service leader perspectives on psychedelic‐assisted therapy for substance use and mental health problems

Addiction, EarlyView.
Abstract Background and aims Australia recently down‐scheduled and authorised psychedelic‐assisted therapies, including psilocybin, for certain mental health conditions. Evidence is emerging for potential application in substance use disorder treatment. However, regulatory developments have outpaced implementation readiness.
Sarah J. Catchlove, Katrin Oliver, Michael Savic, Shalini Arunogiri   +3 more
wiley   +1 more source

L'affaire des « champignons magiques » [PDF]

, 1983
Following a number of acquittals based on a strict interpretation of the terms of the Food and Drugs Act, the Supreme Court of Canada recently had to determine, in Dunn, if a mushroom containing « psilocybin » was a restricted drug despite the fact that ...
Manganas, Antoine
core   +1 more source

Safety pharmacology of acute mescaline administration in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aims Psychedelics, including mescaline, may serve as novel treatments for depression and anxiety. However, data is scarce on the safety of mescaline. Methods The present pooled analysis included two double‐blind, randomized, placebo‐controlled studies with a total of 48 participants and 96 mescaline administrations. Single oral‐dose administrations (n =
Aaron Klaiber, Mélusine Humbert‐Droz, Laura Ley, Yasmin Schmid, Matthias E. Liechti   +4 more
wiley   +1 more source

Class A drug abuse: an ophthalmologist's problem? [PDF]

, 2005
[First Paragraph] The 2002/3 British Crime Survey reported that 3% of all 16 to 59 year olds (equating to around one million people) had used a class A drug in the last year.
Firth, A.Y.
core   +1 more source

Individual and Environmental Factors Associated with Tobacco Smoking, Alcohol Abuse and Illegal Drug Consumption in University Students: A Mediating Analysis [PDF]

, 2020
[Abstract] Substance abuse is a major and prevalent public health concern among university students. Tobacco smoking, risky alcohol behavior, and illegal drug consumption may lead to health problems and behavioral and academic issues. Several individual
Cruz Valiño, José Manuel, Delgado-Lobete, Laura, Gándara Gafo, Berta, Montes-Montes, Rebeca, Santos-del-Riego, Sergio, Talavera Valverde, Miguel Ángel, Vila Paz, Alba   +6 more
core   +1 more source

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

British Journal of Pharmacology, EarlyView.
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander, Dasha Anderson, Luke Baxter, Matthew Claydon, James Rucker, Emma S. J. Robinson   +5 more
wiley   +1 more source

Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder

Translational Psychiatry, 2021
Psilocybin has shown promise for the treatment of mood disorders, which are often accompanied by cognitive dysfunction including cognitive rigidity.
Manoj K. Doss, Michal Považan, Monica D. Rosenberg, Nathan D. Sepeda, Alan K. Davis, Patrick H. Finan, Gwenn S. Smith, James J. Pekar, Peter B. Barker, Roland R. Griffiths, Frederick S. Barrett   +10 more
doaj   +1 more source

Modern Clinical Research on LSD [PDF]

, 2017
All modern clinical studies using the classic hallucinogen lysergic acid diethylamide (LSD) in healthy subjects or patients in the last 25 years are reviewed herein. There were five recent studies in healthy participants and one in patients.
A Garcia-Romeu, A Rickli, A Rickli, AB Wolbach Jr, AL Halberstadt, AL Halberstadt, Andrea E. Steuer, AV Lebedev, CM Hysek, CM Hysek, CS Grob, D Holland, D Marona-Lewicka, D Nutt, DB Terhune, DE Nichols, DE Nichols, DE Nichols, DV Sheehan, E Gouzoulis-Mayfrank, E Studerus, E Tagliazucchi, EA Schindler, F Hasler, F Mueller, FL Osorio, FX Vollenweider, FX Vollenweider, J Riba, J Seibert, J Speth, JC Bouso, JH Halpern, JJ Rucker, KA MacLean, KH Preller, KH Preller, KH Preller, KPC Kuypers, L Roseman, L Roseman, LD Simmler, LE Hollister, M Johnson, M Kaelen, M Kaelen, M Kometer, M Kometer, MA Geyer, Matthias E Liechti, ME Liechti, MJ Baggott, MP Bogenschutz, MW Johnson, P Gasser, P Gasser, P Strajhar, Patrick C. Dolder, PC Dolder, PC Dolder, PC Dolder, PS Hendricks, R Kraehenmann, Rainer Kraehenmann, RE Belleville, RG Dos Santos, RJ Strassman, RJ Strassman, RL Carhart-Harris, RL Carhart-Harris, RL Carhart-Harris, RL Carhart-Harris, RL Carhart-Harris, RL Carhart-Harris, RL Carhart-Harris, RR Griffiths, RR Griffiths, S Ross, SD Muthukumaraswamy, T Passie, TS Krebs, TS Krebs, WE Fantegrossi, WN Pahnke, WN Pahnke, Y Schmid   +85 more
core   +1 more source